On the public citation graph

Successful Therapy of A Critically Ill Nsclc Patient With Uncommon Mutations in Egfr G719x and S768i Genes Using Furmonertinib: A Case Report

0 signed · 10 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/onco.13537openalex-extracted
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
inferredcites →https://doi.org/10.1016/j.canep.2021.102080openalex-extracted
Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
inferredcites →https://doi.org/10.1016/s2213-2600(20)30455-0openalex-extracted
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
inferredcites →https://doi.org/10.1155/2021/9311875openalex-extracted
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
inferredcites →https://doi.org/10.1158/1535-7163.mct-20-0103openalex-extracted
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
inferredcites →https://doi.org/10.1177/0300060520928793openalex-extracted
Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report
inferredcites →https://doi.org/10.1177/1078155220931926openalex-extracted
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
inferredcites →https://doi.org/10.1186/s12885-021-08942-xopenalex-extracted
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
inferredcites →https://doi.org/10.3390/cancers13040804openalex-extracted
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
inferredcites →https://doi.org/10.3390/curroncol29010024openalex-extracted
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.